Literature DB >> 15124024

The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease.

Shreeram Akilesh1, Stefka Petkova, Thomas J Sproule, Daniel J Shaffer, Gregory J Christianson, Derry Roopenian.   

Abstract

The MHC class I family-like Fc receptor, FcRn, is normally responsible for extending the life span of serum IgG Ab's, but whether this molecule contributes to autoimmune pathogenesis remains speculative. To determine directly whether this function contributes to humoral autoimmune disease, we examined whether a deficiency in the FcRn heavy chain influences autoimmune arthritis in the K/BxN mouse model. FcRn deficiency conferred either partial or complete protection in the arthritogenic serum transfer and the more aggressive genetically determined K/BxN autoimmune arthritis models. The protective effects of an FcRn deficiency could be overridden with excessive amounts of pathogenic IgG Ab's. The therapeutic saturation of FcRn by high-dose intravenous IgG (IVIg) also ameliorated arthritis, directly implicating FcRn blockade as a significant mechanism of IVIg's anti-inflammatory action. The results suggest that FcRn is a potential therapeutic target that links the initiation and effector phases of humoral autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15124024      PMCID: PMC398424          DOI: 10.1172/JCI18838

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

Review 1.  Supply, use, and abuse of intravenous immunoglobulin.

Authors:  A Nowak-Wegrzyn; H M Lederman
Journal:  Curr Opin Pediatr       Date:  1999-12       Impact factor: 2.856

Review 2.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn.

Authors:  V Ghetie; E S Ward
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

4.  Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype.

Authors:  S S Pierangeli; R Espinola; X Liu; E N Harris; J E Salmon
Journal:  Arthritis Rheum       Date:  2001-04

Review 5.  Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg.

Authors:  P L Masson
Journal:  J Autoimmun       Date:  1993-12       Impact factor: 7.094

6.  Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

Authors:  T Takai; M Ono; M Hikida; H Ohmori; J V Ravetch
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

7.  Reduced development of CD4-8-B220+ T cells but normal autoantibody production in lpr/lpr mice lacking major histocompatibility complex class I molecules.

Authors:  T Ohteki; M Iwamoto; S Izui; H R MacDonald
Journal:  Eur J Immunol       Date:  1995-01       Impact factor: 5.532

8.  Decreased CD4-CD8- TCR-alpha beta + cells in lpr/lpr mice lacking beta 2-microglobulin.

Authors:  P F Mixter; J Q Russell; F H Durie; R C Budd
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

Review 9.  A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?

Authors:  C Benoist; D Mathis
Journal:  Arthritis Res       Date:  2000-02-24

10.  Greatly reduced lymphoproliferation in lpr mice lacking major histocompatibility complex class I.

Authors:  M A Maldonado; R A Eisenberg; E Roper; P L Cohen; B L Kotzin
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  68 in total

1.  Monoclonal antibodies directed against human FcRn and their applications.

Authors:  Gregory J Christianson; Victor Z Sun; Shreeram Akilesh; Emanuele Pesavento; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis.

Authors:  Caroline G McPhee; Thomas J Sproule; Dong-Mi Shin; Jason A Bubier; William H Schott; Martin P Steinbuck; Lia Avenesyan; Herbert C Morse; Derry C Roopenian
Journal:  J Immunol       Date:  2011-09-30       Impact factor: 5.422

3.  Immune complexes as therapy for autoimmunity.

Authors:  Raphael Clynes
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

4.  Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria.

Authors:  Masaru Yoshida; Kanna Kobayashi; Timothy T Kuo; Lynn Bry; Jonathan N Glickman; Steven M Claypool; Arthur Kaser; Takashi Nagaishi; Darren E Higgins; Emiko Mizoguchi; Yoshio Wakatsuki; Derry C Roopenian; Atsushi Mizoguchi; Wayne I Lencer; Richard S Blumberg
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

Review 5.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 6.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

7.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.

Authors:  Jaspreet Singh Jaggi; Jorge A Carrasquillo; Surya V Seshan; Pat Zanzonico; Erik Henke; Andrew Nagel; Jazmin Schwartz; Brad Beattie; Barry J Kappel; Debjit Chattopadhyay; Jing Xiao; George Sgouros; Steven M Larson; David A Scheinberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  p21Cip1 is required for the development of monocytes and their response to serum transfer-induced arthritis.

Authors:  John C Scatizzi; Jack Hutcheson; Emily Bickel; James M Woods; Karolina Klosowska; Terry L Moore; G Kenneth Haines; Harris Perlman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

Review 9.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

10.  Activation of the JAK/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG.

Authors:  Xindong Liu; Lilin Ye; Yu Bai; Habi Mojidi; Neil E Simister; Xiaoping Zhu
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.